1. Home
  2. KRG vs BLCO Comparison

KRG vs BLCO Comparison

Compare KRG & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kite Realty Group Trust

KRG

Kite Realty Group Trust

HOLD

Current Price

$26.08

Market Cap

5.3B

Sector

Real Estate

ML Signal

HOLD

Logo Bausch + Lomb Corporation

BLCO

Bausch + Lomb Corporation

HOLD

Current Price

$15.89

Market Cap

5.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KRG
BLCO
Founded
1971
1853
Country
United States
Canada
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Ophthalmic Goods
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.3B
5.9B
IPO Year
2004
2022

Fundamental Metrics

Financial Performance
Metric
KRG
BLCO
Price
$26.08
$15.89
Analyst Decision
Buy
Buy
Analyst Count
10
12
Target Price
$26.00
$18.45
AVG Volume (30 Days)
1.6M
362.5K
Earning Date
04-29-2026
04-29-2026
Dividend Yield
4.47%
N/A
EPS Growth
6750.00
N/A
EPS
1.37
N/A
Revenue
$844,365,000.00
$5,101,000,000.00
Revenue This Year
N/A
$8.65
Revenue Next Year
$0.96
$5.59
P/E Ratio
$18.96
N/A
Revenue Growth
0.30
6.47
52 Week Low
$20.86
$10.45
52 Week High
$26.82
$18.92

Technical Indicators

Market Signals
Indicator
KRG
BLCO
Relative Strength Index (RSI) 58.69 42.52
Support Level $21.84 $14.27
Resistance Level $26.29 $17.11
Average True Range (ATR) 0.43 0.39
MACD 0.06 -0.05
Stochastic Oscillator 64.95 18.00

Price Performance

Historical Comparison
KRG
BLCO

About KRG Kite Realty Group Trust

Kite Realty Group Trust specializing in high-quality, open-air shopping centers and mixed-use assets. Concentrated in the Sun Belt and strategic gateway markets, the company focuses on grocery-anchored, necessity-based retail. The company generates the majority of its revenue from contractual rents and reimbursement payments received from tenants.

About BLCO Bausch + Lomb Corporation

Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.

Share on Social Networks: